Immune Reconstitution After Autologous Hematopoietic Stem Cell Transpl for High-Risk Lymphoma
Completed · Not applicable
Conditions studied: Lymphoma, Multiple Myeloma and Plasma Cell Neoplasm, Small Intestine Cancer
In brief
RATIONALE: Vaccines may help the body build an effective immune response to kill cancer cells. Giving vaccine therapy after an autologous stem cell transplant may kill any cancer cells that remain after transplant. PURPOSE: This clinical trial is studying how well vaccine therapy works in treating patients who have undergone autologous stem cell transplant for high-risk lymphoma or multiple myeloma.
Key facts
- Study ID
- NCT00569309
- Run by
- Ohio State University Comprehensive Cancer Center
- People needed
- 30
- Starts
- 2007-12-12
- Expected to finish
- 2011-07-29
- Last updated by the study team
- 2018-03-12
Who can join
Age: 18 and older. Sex: any. Healthy volunteers: not accepted.
Where it is running
- Arthur G. James Cancer Hospital and Richard J. Solove Research Institute at Ohio State University Comprehensive Cancer Center — Columbus, Ohio, United States
Full record on ClinicalTrials.gov
Trial information comes from ClinicalTrials.gov and is refreshed daily. TrialsForMe does not provide medical care and does not run the studies it lists.